IMPORTANCE Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma. In rare cases, the development of an additional cutaneous MCC tumor is clinically consistent with a second primary MCC tumor rather than a cutaneous metastasis, which has important treatment and prognostic implications.
M erkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine neoplasm and presents as a redto-violaceous nodule, typically on sun-exposed skin of older individuals.
1 At the time of diagnosis of the primary tumor, there is at least a 15% to 20% risk of clinically occult metastasis to the regional nodal basin. [2] [3] [4] The most common site of metastasis is the regional lymph node basin, followed by skin, lung, liver, bone, and other sites of distant metastasis. Evidence suggests that MCC may arise via 2 pathways: a virus-associated pathway mediated by the integration of the oncogenic Merkel cell polyomavirus (MCPyV) or an ultraviolet light-damage pathway associated with a high mutation burden, ultraviolet light-signature mutations, and inactivation of the tumor suppressors RB1 and TP5.
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The phenomenon of multiple primary tumors has been observed in melanoma, where distinct cutaneous primary tumors are clonally unrelated. 8 Importantly, the designation of an additional distinct primary melanoma impacts management, as the lesion is treated as a primary melanoma with excision and possibly additional staging with sentinel lymph node biopsy, rather than a distant cutaneous metastasis. Following a diagnosis of MCC, the development of additional cutaneous tumors, whether adjacent to the treated primary site, within the draining lymphatics or on distant skin, is usually thought to represent a local, in-transit or distant cutaneous recurrence of the original tumor. However, in rare cases, patients may present with a second cutaneous MCC that is spatially and/or temporally separated such that the lesion is clinically designated an independent primary MCC rather than a cutaneous metastasis. [9] [10] [11] [12] [13] [14] [15] [16] Given the rarity of multiple primary MCCs, genetic relatedness has been evaluated only in 3 cases that we know of. 11, 15, 16 One case demonstrated genetic unrelatedness by analyzing sequences of the integrated MCPyV, 11 and the other cases demonstrated clonality by comparative genomic hybridization analysis of chromosomal copy number changes. 15, 16 The distinction between 2 primary tumors and a primary-metastasis pair has significant impact on treatment and prognosis. Next-generation sequencing (NGS), which provides a broad profile of mutations and chromosomal copy number alterations (CNAs) within a tumor, is ideally suited for clonality analysis. 17 In this study, we evaluate clonal relatedness in 4 patients with clinically designated multiple primary MCCs using NGS.
Methods

Cohort
All studies were conducted according to protocols previously approved by the institutional review board of the University of Michigan; archival formalin-fixed, paraffinembedded tissues collected for diagnostic purposes were used according to waiver of consent protocol approved by the institutional review board. Seven MCC cases (14 tumors) designated as multiple primary tumors (distant metastases not suspected) were identified from a database of 473 cases at the Multidisciplinary MCC Program at the University of Michigan from January 2006 through April 2016 (eMethods in the Supplement). Inclusion criteria were availability of paraffin blocks, adequate tumor for sequencing, and adequate quality DNA for NGS analysis; 4 cases (8 tumors) met these criteria. For case 4, a matched regional lymph node metastasis was also sequenced. Metastases in other cases did not yield adequate tumor purity or DNA quantity and/or quality for inclusion. Clinicopathologic features are summarized in Table 1 . Two primary-metastasis pairs previously sequenced by the same methods were included in analysis. 18 
Targeted NGS
Targeted NGS assessing the complete coding sequence of 409 cancer related genes on archived formalin-fixed, paraffin-embedded (FFPE) material to identify somatic mutations and CNAs was performed using the Ion Ampliseq Comprehensive Cancer Panel (CCP) (Thermo Fisher Scientific) as described previously 18, 19 and in eMethods in the Supplement.
Somatic Variant Identification
Results
Cases
Seven cases were identified in which a second MCC tumor was clinically designated a second primary tumor rather than a recurrence or distant metastasis. Four cases had sufficient quantity and quality of DNA for clonality assessment. The clinical histories of the 4 analyzed cases are summarized in Table 1 .
Case 1 A man in his 70s was diagnosed with a primary MCC on the left third finger. He underwent amputation and sentinel lymph node biopsy (SLNB) revealing clear margins at the primary site and 2 negative sentinel lymph nodes (SLNs) from the left axilla. He did not undergo adjuvant radiation therapy. Six months later, biopsy of a lesion on his right (contralateral) first finger showed MCC. Restaging imaging was negative for metastatic disease. He underwent excision and SLNB revealing clear margins at the primary site and 3 negative SLNs from the right axilla. Adjuvant radiation therapy was not indicated. He has been free of disease since treatment of the presumed second primary MCC almost 6 years ago.
Case 2
A man in his 80s was diagnosed with a primary MCC on the left elbow. He underwent excision with clear margins and left axillary SLNB interpreted as negative at an outside institution. Nineteen months later, biopsy of a cutaneous lesion on his left thigh revealed MCC, at which time he presented to the University of Michigan for further evaluation. Upon review, the initial left axillary SLNB was found to be positive for microscopic MCC in 1 of 2 lymph nodes. Therefore, at the time, the newly diagnosed lesion on the thigh was presumed to be a distant cutaneous metastasis. Restaging imaging was negative for metastatic disease. The lesion on the thigh was excised, but SLNB or adjuvant therapy was not recommended based on the presumption of stage IV disease. Four months later, he developed a nodal MCC metastasis in the left groin. Inguinal lymph node dissection revealed 2 of 26 lymph nodes positive for MCC. He did not undergo adjuvant radiation therapy. At this point, based on patterns of metastasis, the tumors were considered to represent 2 primary MCCs, each with regional nodal metastases. The patient has been free of disease for nearly 4 years since the left inguinal lymph node dissection.
Case 3
A woman in her 70s was diagnosed with 2 concurrent MCCs on the left and right nasal alae. Staging imaging did not demonstrate metastatic disease. The lesions were designated as 2 primary tumors, and she underwent excision and SLNB for both sites. Pathology revealed clear margins at both primary sites and 2 of 4 positive SLNs in the left neck, and 3 negative SLNs in the right neck. Based on the uncertain clinical presentation, the patient underwent bilateral neck dissection revealing additional 23 and 41 negative lymph nodes in the left and right neck, respectively. She did not undergo adjuvant radiation and has been free of disease for 1.3 years after surgery.
Case 4
A man in his 70s was diagnosed with a large primary MCC on the left cheek with a concurrent nodal metastasis in the left parotid gland. He underwent excision, parotidectomy, and left neck dissection, which revealed a positive deep margin at the primary site and 9 of 20 lymph nodes positive for metastatic MCC. He underwent adjuvant radiation therapy to the left 
MCPyV Status
Overall, 6 of 8 (75%) of the primary tumors in cases 1 through 4 harbored MCPyV large and small T antigen sequences ( Figure 1 ; Table 1 ) (eFigure 1 in the Supplement). Both tumors from a given patient had similar MCPyV copy number (Table 1) . One patient (case 4) lacked detectable MCPyV in the 2 primary tumors ( Figure 1 ; Table 1 ) (eFigure 1 in the Supplement). In 5 tumors, adequate DNA remained for partial sequencing of the MCPyV large T antigen exon 2, revealing identical sequences across all cases, without tumor-specific mutations in the analyzed region (eTable 2 in the Supplement).
Mutational and Copy Number Analysis of MCC
We assessed somatic, high-confidence mutations and copy number alterations in 409 cancer-related genes across the primary tumors from the 4 cases, as well as a regional lymph node metastasis in case 4. Results are summarized in Table 1 and Table 2 , with additional details in eTables 3 and 4intheSupplement. Recurrent events that suggest clonality were identified in a subset of paired tumors, as described in clonality analysis below ( Figure 2 ) (eTable 4 in the Supplement).
Clonality Analysis of MCC Tumor Pairs
Clonality was evaluated in the clinically designated multiple primary MCC tumors by quantitating the fraction of shared genetic events in a pair using the similarity index calculation. 22 To determine the expected range of overlap for clonally related MCC tumors, we first assessed genetic similarity in the primary MCC tumor and matched regional metastasis from case 4, as well as 2 primary-metastasis pairs (MCC9-MCC14 and MCC10-MCC16; cases 5 and 6) (eTable 5 in the Supplement) previously sequenced using an identical approach. 18 Primary MCC tumor-metastasis pairs (n = 3) displayed similarity indices, ranging from 0.21 to 1.0 for CNA and 0.09 to 0.0.91 for mutational analysis ( Figure 3) . Thus, CNA and mutational similarity indices greater than 0.21 and 0.09, respectively, were used as the minimum scores representing likely clonal relatedness. Analysis of random pairings (primary tumors from different patients, representing 24 total pairings of cases 1-4), served as a negative control for clonality analysis and displayed no similarities (similarity index = 0 for both CNA and mutational analyses). For case 1, similarity indices were 0 (not clonal) and 0.014 (not clonal), for CNA and mutational analyses, respectively. For case 2, similarity indices were 0.8 (clonal) and 0 (not clonal) for CNA and mutational analyses, respectively. For case 3, similarity indices were 0.67 (clonal) and 0 (not clonal) for CNA and mutational analyses, respectively. For case 4, similarity indices were 0 (not clonal) for both CNA and mutational analyses. In summary, cases 1 and 4 were confirmed as independent primary tumors without genetic overlap, while cases 2 and 3 demonstrated genetic relatedness in chromosomal copy number changes and were designated as clonally related (Figures 2 and 3) .
To evaluate the discrepancy in the clonality results between CNA and mutational analyses, we evaluated the allele frequency of mutations. Mutations in MCPyV-negative tumors were observed at an average allele frequency of 49.2%, consistent with heterozygous mutations present in most or all Multiple primary MCCs were verified in case 1 (second primary MCC arising on contralateral hand) and case 4 (second primary MCC arising on contralateral cheek) as the tumor pairs did not harbor similar copy number alterations or significant mutational overlap (Table 1) . In case 4, tumors displayed distinct TP53 and RB1 mutations, consistent with the proposed role for inactivation of these tumor suppressor genes as driving, early events in MCPyV-negative MCC. 5, 27 Of note, in case 1, which was MCPyV-positive, a limited number of discordant CNAs drove the determination of multiple primary MCC status, as identified mutations in each sample were nonprioritized and subclonal based on variant allele frequency assessment. Clonal relatedness was identified in case 2 (MCC on left elbow and subsequently on left thigh) and case 3 (MCCs on bilateral nasal alae). In case 2, both tumors shared multiple copy number changes, that are predicted to be early events, compared with mutations arising later. Although speculative, we hypothesize that the second MCC tumor on the left thigh arose from hematogenous spread from the primary tumor or the untreated left axillary nodal metastasis and that the nodal recurrence in the left groin was from lymphatic drainage from the left thigh metastasis. In case 3, both tumors displayed significant overlap in CNAs. Given the synchronous occurrence, these tumors likely represent a primary and in-transit metastasis pair. A less likely scenario is that both tumors represent in-transit metastases from a regressed midline primary tumor. by array comparative genomic hybridization analysis in a patient with a primary tumor on the right cheek and the second tumor on the left leg 2 months later. Nagy et al 16 used comparative genomic hybridization analysis to demonstrate shared and distinct molecular patterns in a primary MCC tumor on the lip and a second tumor on the palatine tonsil 7 years later. Nagy et al 16 conclude that the second tumor was an independent primary MCC with a field effect from the first tumor. Given the genetic overlap, we and others interpret these tumors to be clonally related.
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Merkel cell polyomavirus is found to be integrated in up to 80% of MCCs. 29 Interestingly, we found that tumors from the same patient were consistently MCPyV negative or MCPyV positive, regardless of clonal relatedness. Although our cohort is small, this observation suggests that a given patient may be predisposed to development of either MCPyV-negative or MCPyV-positive MCC. Furthermore, MCPyV status alone is not a reliable indicator of clonal relatedness between MCC tumors.
Limitations
This study has several limitations. The occurrence of clinically designated multiple primary MCCs is exceedingly rare, which limits appropriate cases with tissue suitable for analysis. However, that we know of, this series represents the largest to date, the first to use NGS for clonality analysis, and the only study to analyze clonality in multiple primary MCCs by multiple parameters in parallel: mutations, CNAs, and MCPyV sequence. Of these, we found CNA similarity to be a more consistent indicator of clonality than mutations in genetically related tumors, thus mutation analysis is less informative in this context. In particular, MCPyV-positive MCC has low mutational burden, with the vast majority of somatic mutations being subclonal, nondriving mutations, which may explain why examination of tumor mutations was not reliable for demonstrating clonality in these tumors. Unlike a previous study, we did not find MCPyV sequence analysis to be useful in evaluating clonal relatedness, as all MCPyV-positive tumors displayed high similarity in viral sequence. However, coverage of the MCPyV sequence was limited in many cases due to low remaining material; therefore, we cannot exclude the possibility that more extensive analysis of viral sequences might be informative. Likewise, we only assessed a portion of the tumor genome, and hence, are unable to assess fine subclonal structure in the related tumors. However, the purpose of our study was to assess clonal relatedness between 2 apparent primary tumors, not detailed intratumoral or intertumoral heterogeneity.
Conclusions
Our findings show that patients with MCC may develop a second genetically distinct primary tumor, which is likely to develop through similar mechanisms of pathogenesis. Our study also supports clonality, and hence metastasis, in 2 cases of presumed multiple primary tumors. These findings underscore the challenge to correctly distinguish a second primary MCC from an isolated distant cutaneous metastasis, which has critically important prognostic and therapeutic implications. Our findings also support copy number analysis as more effective than mutational analysis for determining clonality in MCC, including MCPyV-positive tumors with low mutational burden. Given that clinicopathologic criteria may be imperfect, as seen in multiple primary lung carcinoma, 30 copy number analysis by array comparative genomic hybridization or NGS may assist in the determination of clonality in clinically challenging cases.
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eMethods Cohort
MCC cases that were clinically designated as multiple primary tumors were identified from a database of 473 cases compiled by the Multidisciplinary MCC Program. All cases were discussed at the Multidisciplinary MCC tumor board for consensus treatment recommendations. For a clinical designation of distinct primary tumors, MCC tumors were either spatially and/or temporally separated such that a cutaneous local recurrence or in-transit metastasis was not suspected. Re-staging with imaging studies at the time of the second primary tumor was negative for distant stage IV disease.
Targeted Next Generation Sequencing
Targeted NGS assessing the complete coding sequence of 409 cancer related genes on archived FFPE (formalin-fixed paraffin embedded) material to identify somatic mutations and CNAs was performed using the Ion Ampliseq Comprehensive Cancer Panel (CCP) as described previously 1, 2 . Briefly, DNA was isolated from macrodissected FFPE sections using the Qiagen Allprep FFPE DNA/RNA kit (Qiagen, Valencia, CA). DNA was quantified using the Qubit 2.0 fluorometer (Life Technologies, Foster City, CA). Barcoded libraries were generated using 40ng of DNA amplified using the Ion AmpliSeq Library 
Somatic Variant Identification
NGS data analysis was performed essentially as described 1,2 using in house pipelines based on Torrent Suite 4.0 and Torrent Mapping Alignment Program using default parameters. Single nucleotide variants (SNVs) and insertions/deletions (indels) were identified using the Torrent Variant Caller plugin using default low-stringency somatic variant settings. Called variants were filtered to remove non-coding variants, those with flow corrected read depths (FDP) ≤50, flow corrected variant allele containing reads (FAO) ≤6, variant allele frequencies (FAO/FDP) <0.10, extreme skewing of forward/reverse flow corrected reads (FSAF/FSAR <0.2 or >5), or indels within homopolymer runs >4 bases. Variants occurring exclusively in reads with other single nucleotide variants or indels and those occurring in the last mapped base of a read were excluded. Additionally, any variants called in >4% of internally sequenced samples using the same panel and not reported in COSMIC were removed. Nonsynonymous variants seen in more than 6 samples sequenced on the same panel and not observed in COSMIC were also excluded. Variants present in ESP6500 or 1000 Genomes (from Annovar) as well as variants present in the ExAC database (http://exac.broadinstitute.org) that are not at known COSMIC hotspots were considered germ line variants and removed. All high confidence variants passing the above criteria were then visualized in IGV. We have previously demonstrated that our filtering criteria identify variants that pass Sanger sequencing validation with >95% accuracy. From these somatic variants, hotspots (>1 observation at that residue in COSMIC) in oncogenes, or hotspot or deleterious alterations (nonsense/frameshift variants) in tumor suppressors were then considered as prioritized variants.
Copy Number Analysis
To identify copy number alterations (CNAs), for each sample, normalized GC content corrected read counts per amplicon were divided by those from a composite "normal" male DNA sample generated from multiple individual and pooled normal FFPE tissues, yielding a copy number ratio for each amplicon as described [1] [2] [3] . Gene-level copy number estimates were determined by taking the coverage-weighted mean of the per-probe ratios, with expected error determined by the probe-to-probe variance. Library quality parameters are described in Supplemental Table S5 .
Clonality Analysis
Similarity index was calculated as previously described 4 using the equation:
Where N S = number of shared changes, N O = number of opposite changes, and N U = number of unique changes. Shared changes were counted once between cases (e.g. the DST c.A3835G mutation identified in both MCC28 and MCC29 was counted as a single shared change for the similarity index calculation). No events were in the "opposite changes" category in our cases. For mutational analysis, variant calls were considered to be shared events if they demonstrated the same nucleotide change at the same nucleotide position in a given gene.
MCPyV PCR
Detection of MCPyV sequences in tumor DNA was performed by qPCR as previously described 5, 6 . Primer/probe sets were LT2 (large T antigen) and SET9 (small T antigen), with cell line controls including MKL2 (MCC, positive control) and A375 (melanoma, negative control).
MCPyV genomic sequencing was performed by PCR-Sanger using previously reported primers 7 as well as custom primers targeting the 5' region of LTAg exon 2 and optimized for FFPE (Supplemental Table S2 ). Sanger sequencing was performed at the University of Michigan DNA Sequencing Core as previously described 
